Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Dragonfly Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
National Cancer Institute (NCI)
Dragonfly Therapeutics
BeOne Medicines
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Avacta Life Sciences Ltd
Janssen Research & Development, LLC
Stanford University
Boehringer Ingelheim
Incyte Corporation
Pfizer
Boehringer Ingelheim
ArriVent BioPharma, Inc.
Seagen Inc.
University of Iowa
Johnson & Johnson Enterprise Innovation Inc.
Seagen Inc.
Ono Pharmaceutical Co. Ltd
Eli Lilly and Company
Pfizer
Novartis
Fred Hutchinson Cancer Center
Exelixis
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
EpiBiologics
Emory University
University Hospital Heidelberg
AstraZeneca
Alterome Therapeutics, Inc.
M.D. Anderson Cancer Center
Ankyra Therapeutics, Inc
Daiichi Sankyo
University Health Network, Toronto
City of Hope Medical Center